Two preclinical advances demonstrated therapeutic potential for in‑vivo base editing delivered by lipid nanoparticles. Researchers used lipid nanoparticle formulations to mediate base editing of the RHO c.1030C>T (p.Q344X) rhodopsin mutation linked to retinitis pigmentosa, achieving correction in retinal tissues and functional benefit in models. The work highlights LNPs as a nonviral route to ocular gene editing. Separately, in vivo base editing corrected two major phenylketonuria (PKU) variants in mice, restoring phenylalanine metabolism and offering a one‑time genetic correction approach described in the preclinical literature. Both studies emphasize precision editing chemistries coupled with delivery systems that limit systemic exposure. These results advance the conversation about scalable, nonviral delivery for clinical gene editing and will inform IND strategies, dosing, and safety assessments as teams plan translational studies.